LIPID UPDATE 2014
Holiday Inn Stratford Upon Avon *STRATFORD UPON AVON, UK Visit the Venue to read more
We are pleased to announce Lipid Update XIII, which will be a two day meeting held at the Holiday Inn Stratford-upon-Avon.
The meeting is designed for full-time practising UK doctors (consultants and SpRs in the fields of general medicine, cardiology, nephrology, diabetes, biochemists, chemical pathologists and geriatrics). However, places may be allocated to other healthcare professionals, depending on availability.
The Lipid Update series started in 1993, and feedback from delegates attending these meetings has been extremely positive, encouraging us to organise what we are sure will be another successful sequel.
The new programme for this year’s meeting includes a comprehensive review of lipid disorders and their management, as well as sessions covering current and emerging issues. We should also like to encourage you to submit your own difficult cases for discussion with the faculty and audience in the closing session.
CPD Accreditation from the Royal College of Physicians in the UK will be applied for. Delegates will need to sign the CPD register and certificates of attendance will be available at the end of the meeting.
We wish to thank our supporter for their unrestricted educational grant and we look forward to welcoming you to Stratford-upon-Avon this November.
Professor John Betteridge
Professor Neil Poulter
Professor Peter Sever
Professor Simon Thom
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Holiday Inn Stratford-upon-Avon
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.